Benjamin Derman

Dr. Benjamin Derman and Dr. Manni Mohyuddin discuss updates in Minimal Residual Disease (MRD) in multiple myeloma, including the potential use of MRD as a surrogate endpoint for accelerated FDA approval. They explore the benefits and challenges of achieving MRD negativity, advancements in MRD detection technologies, implications of MRD resurgence, and the impact of MRD negativity on treatment decisions and discontinuation. The podcast sheds light on the complexities of utilizing MRD in myeloma treatment strategies.

Experts discuss the challenges of sequencing BCMA therapies in multiple myeloma, the prognostic value of circulating tumor cells, and the growing role of quadruplet therapies. They explore optimal combinations and sequencing, the Perseus trial comparing DARA VRD and VRD treatments, and the use of Dara KRD for newly diagnosed myeloma patients.